ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (ACAD) Revenue
Annual & quarterly revenue history · segment & region breakdown
ACAD · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsACADIA Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $1.10B, an increase of 11.87% year-over-year from $1.07B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.07B | +$0.11B | +11.87% |
| 2024-12-31 | $0.96B | +$0.23B | +31.85% |
| 2023-12-31 | $0.73B | +$0.21B | +40.45% |
| 2022-12-31 | $0.52B | +$0.03B | +6.83% |
| 2021-12-31 | $0.48B | +$0.04B | +9.60% |
| 2020-12-31 | $0.44B | +$0.10B | +30.28% |
| 2019-12-31 | $0.34B | +$0.12B | +51.50% |
| 2018-12-31 | $0.22B | +$0.10B | +79.19% |
| 2017-12-31 | $0.12B | +$0.11B | +620.68% |
| 2016-12-31 | $0.02B | +$0.02B | +28311.48% |
Compare revenue vs peers
BiotechnologyCompare ACAD revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ACADIA Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ACADIA Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ACADIA Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ACAD revenue · 4 questionsACAD's trailing twelve-month (TTM) revenue is $1.10B. That is an increase of 11.87% year-over-year from $1.07B in FY2025.
▸ Source: FMP · ACADIA Pharmaceuticals Inc. SEC filings · GAAP · ACADIA Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026